Latest Research Development News

Universal Biosensors reported a 44% increase in net loss to A$10.45 million for H1 2025, alongside an 11% revenue decline, raising serious going concern doubts. The company is pursuing an A$8.5 million senior secured loan and equity raise to sustain operations.

Syntara Limited reported a $3.7 million cash outflow from operations in the June quarter but bolstered its balance sheet with an $18.5 million capital raise, ending the period with $15.1 million in cash.

BirdDog Technology Limited reported a 6.9% increase in quarterly sales to A$4.3 million, driven by the successful launch of two next-generation broadcast products and a strong cash position ahead of a planned share buy-back.

Beetaloo Energy Australia Limited reported significant cash outflows from exploration activities in Q2 2025, balanced by strong financing inflows that secure its liquidity for the near term.

Lincoln Minerals has identified multiple high-priority drill targets at its Minbrie Copper-Base Metals Project with drilling planned for late 2025, while its Kookaburra Graphite Project achieves battery-grade purity, underscoring the company’s strategic positioning in critical minerals.

Identitii Limited has refinanced a $0.8 million loan with an interest-free facility from its largest shareholder, Beauvais Capital, reducing interest expenses and freeing up company assets.

WA Kaolin Limited reports robust production growth and expanding sales, driven by new technical kaolin grades and strong forward orders for FY26.

Spenda Limited has reported a record-breaking FY25 with cash receipts soaring 114% to $11.5 million and launched its APG Pay platform backed by a $50 million funding commitment. The company also trimmed operating costs by 39%, setting a leaner foundation for FY26 growth.

LTR Pharma has initiated commercial distribution of its nasal spray SPONTAN through Australia's Symbion pharmacy network and is advancing ROXUS development for a US launch in early 2026, while expanding its pipeline with a new intranasal treatment for swallowing disorders.

Advanced Health Intelligence Ltd (AHI) reports robust commercial progress and strategic funding moves in Q1 2025 despite ongoing ASX trading suspension and recent NASDAQ delisting. Key partnerships and technology validations position the company for a strong global scale-up.

Race Oncology has safely treated the first patient with its RC220 drug alone and in combination with doxorubicin in a Phase 1 trial, while bolstering its clinical leadership and maintaining a strong cash position to fund operations through 2026.

InhaleRx Limited has secured key ethics approvals and initiated manufacturing for its inhaled drug candidates targeting breakthrough cancer pain and panic disorder, supported by a $38.5 million funding facility to accelerate development.